Acutaas Chemicals Hits Record High of ₹2,727; Stock Surges 138% on Battery and Semi-Conductor Pivot

Synopsis:-Having rebranded from Ami Organics to Acutaas Chemicals in May 2025, the company hit a fresh all-time high of Rs. 2,725 on May 6, 2026, delivering a 138 percent return over the past year, as investors price in the convergence of three near-term catalysts: commercial battery chemical supply from mid-2026, revenue from its Korea semiconductor JV in early 2027, and management’s Rs. 1,000 crore CDMO target by FY28.

Shares of a Surat-based specialty chemicals company touched a record high on Wednesday, extending a multi-month re-rating as the market absorbs the scale and direction of the company’s pivot across semiconductor materials, EV battery chemicals, and CDMO services. The moves, executed over the past 18 months, amount to one of the more complete portfolio overhauls attempted by a mid-cap Indian specialty chemicals company in recent years.

With a market capitalization of approximately Rs. 22,318.07 crore, the shares of Acutaas Chemicals Limited were trading at Rs. 2,727.2  per share on May 6, 2026, up 2.65 percent from a previous close of approximately Rs. 2,656.7. The stock trades at a P/E of approximately 61.03.

The name change from Ami Organics to Acutaas Chemicals, effective May 15, 2025, was not cosmetic. The new identity was intended to signal an explicit break from the company’s older identity as a pharmaceutical active pharmaceutical ingredient supplier and signal intent toward high-specification, high-barrier chemical segments. Alongside the rebranding, the company received the EcoVadis Platinum rating, placing it in the top one percent of globally rated companies for sustainability. For a company seeking qualification audits with global semiconductor and EV customers, this credential is operationally relevant, not decorative.

Korea Semiconductor JV: Indichem

The most capital-intensive of the company’s moves is its joint venture plant in Gongju, South Korea, developed through Indichem, a partnership with J&Materials. The facility, backed by an investment of approximately 30 billion won (roughly Rs. 185 crore), will produce ultra-pure photoresist materials, a class of chemicals used in semiconductor lithography where purity tolerances are measured in parts per billion and even minor deviations disqualify suppliers from customer rosters. Construction is on track for completion in the second half of 2026, with commercial revenue expected from early 2027 after customer qualification audits across the Korea, Taiwan, and Japan electronics supply chains. The qualification process is the gating factor. Once cleared, supplier switching costs are high enough to make these relationships durable. Until audits pass, the Rs. 185 crore investment earns nothing.

Battery Chemicals: VC and FEC

Closer to realisation is the battery chemicals business. Acutaas is set to begin commercial supply of electrolyte additives specifically Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC), both performance-critical additives used in lithium-ion battery electrolytes from mid-2026. Unlike the Korea plant, this revenue is backed by long-term customer contracts already in place, making it arguably the most de-risked of the three growth vectors. Management has guided that these contracts provide visibility for approximately three years, as battery manufacturers diversifying away from Chinese chemical supply chains are actively seeking qualified Indian alternatives. FY27 is the first full year in which battery chemicals revenue will be visible in the financials.

Acutaas is building a new R&D centre with four distinct divisions covering pharmaceuticals and CDMO, battery chemicals, semiconductors and electronics, and cosmetics and personal care. Separately, the company is actively phasing out low-margin commodity chemical lines to concentrate capital and management bandwidth on patent-protected or high-barrier molecules.

The stated long-term target is Rs. 1,000 crore in CDMO revenues by FY28. At FY26’s consolidated revenue of approximately Rs. 1,339 crore, this would imply CDMO alone approaching current total revenues, a signal that the business mix the company is building looks materially different from today’s. Capex for FY26 was guided at Rs. 220 crore, with Rs. 130 crore earmarked for the Indichem JV.

Business Overview

Originally incorporated in 2004 as a partnership firm, Acutaas Chemicals Limited (formerly Ami Organics Limited) is listed on both NSE and BSE. The company manufactures pharmaceutical intermediates and specialty chemicals at its facilities in Gujarat.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Acutaas Chemicals Hits Record High of ₹2,727; Stock Surges 138% on Battery and Semi-Conductor Pivot appeared first on Trade Brains.